Enliven Therapeutics Statistics
Total Valuation
ELVN has a market cap or net worth of $1.29 billion. The enterprise value is $817.29 million.
Important Dates
The last earnings date was Wednesday, November 12, 2025, after market close.
| Earnings Date | Nov 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ELVN has 59.35 million shares outstanding. The number of shares has increased by 19.30% in one year.
| Current Share Class | 59.35M |
| Shares Outstanding | 59.35M |
| Shares Change (YoY) | +19.30% |
| Shares Change (QoQ) | +19.17% |
| Owned by Insiders (%) | 4.09% |
| Owned by Institutions (%) | 68.50% |
| Float | 37.33M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.71 |
| P/TBV Ratio | 2.72 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 32.95, with a Debt / Equity ratio of 0.00.
| Current Ratio | 32.95 |
| Quick Ratio | 32.60 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -25.43% and return on invested capital (ROIC) is -18.34%.
| Return on Equity (ROE) | -25.43% |
| Return on Assets (ROA) | -17.62% |
| Return on Invested Capital (ROIC) | -18.34% |
| Return on Capital Employed (ROCE) | -23.57% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.57M |
| Employee Count | 62 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -8.01% in the last 52 weeks. The beta is 1.07, so ELVN's price volatility has been similar to the market average.
| Beta (5Y) | 1.07 |
| 52-Week Price Change | -8.01% |
| 50-Day Moving Average | 20.84 |
| 200-Day Moving Average | 20.03 |
| Relative Strength Index (RSI) | 54.95 |
| Average Volume (20 Days) | 511,843 |
Short Selling Information
The latest short interest is 7.79 million, so 13.13% of the outstanding shares have been sold short.
| Short Interest | 7.79M |
| Short Previous Month | 7.78M |
| Short % of Shares Out | 13.13% |
| Short % of Float | 20.88% |
| Short Ratio (days to cover) | 13.74 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -112.27M |
| Pretax Income | -97.21M |
| Net Income | -97.21M |
| EBITDA | -111.97M |
| EBIT | -112.27M |
| Earnings Per Share (EPS) | -$1.81 |
Full Income StatementBalance Sheet
The company has $477.57 million in cash and $490,000 in debt, giving a net cash position of $477.08 million or $8.04 per share.
| Cash & Cash Equivalents | 477.57M |
| Total Debt | 490,000 |
| Net Cash | 477.08M |
| Net Cash Per Share | $8.04 |
| Equity (Book Value) | 476.12M |
| Book Value Per Share | 8.03 |
| Working Capital | 468.03M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$71.67 million and capital expenditures -$158,000, giving a free cash flow of -$71.82 million.
| Operating Cash Flow | -71.67M |
| Capital Expenditures | -158,000 |
| Free Cash Flow | -71.82M |
| FCF Per Share | -$1.21 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |